Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.

Antimicrobial Agents and Chemotherapy
John A BossoPatrick D Mauldin

Abstract

Several single-center studies have suggested that higher doses of vancomycin, aimed at producing trough concentrations of >15 mg/liter, are associated with increased risk of nephrotoxicity. We prospectively assessed the relative incidence of nephrotoxicity in relation to trough concentration in patients with documented methicillin-resistant Staphylococcus aureus (MRSA) infections at seven hospitals throughout South Carolina. Adult patients receiving vancomycin for at least 72 h with at least one vancomycin trough concentration determined under steady-state conditions were prospectively studied. The relationship between vancomycin trough concentrations of >15 mg/ml and the occurrence of nephrotoxicity was assessed using univariate and multivariate analyses, controlling for age, gender, race, dose, length of therapy, use of other nephrotoxins (including contrast media), intensive care unit (ICU) residence, episodes of hypotension, and comorbidities. Nephrotoxicity was defined as an increase in serum creatinine of 0.5 mg/dl or a ≥ 50% increase from the baseline for two consecutive measurements. MICs of vancomycin for the MRSA isolates were also determined. A total of 288 patients were studied between February 2008 and June 2010, w...Continue Reading

References

Jul 8, 1999·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·M A Abramson, D J Sexton
Dec 20, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sara E CosgroveYehuda Carmeli
Feb 21, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John J EngemannKeith S Kaye
Jan 17, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patrick G P CharlesM Lindsay Grayson
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kyu Y RheeMacarthur Charles
Nov 29, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Michael J FischerChirag R Parikh
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael J Rybak
Oct 25, 2006·Archives of Internal Medicine·Levita K HidayatAnnie Wong-Beringer
Oct 18, 2007·JAMA : the Journal of the American Medical Association·R Monina KlevensUNKNOWN Active Bacterial Core surveillance (ABCs) MRSA Investigators
Jan 30, 2008·Antimicrobial Agents and Chemotherapy·Thomas P LodiseG L Drusano
Apr 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Keith S KayeDaniel J Sexton
Aug 13, 2008·The Journal of Antimicrobial Chemotherapy·T P LodiseK Stellrecht
Oct 25, 2008·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Alicia I HidronUNKNOWN Participating National Healthcare Safety Network Facilities
Nov 13, 2008·Antimicrobial Agents and Chemotherapy·Avisheh ForouzeshGeorge Sakoulas
Dec 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael RybakDonald P Levine
Jul 10, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseGeorge L Drusano
Jun 19, 2010·Chest·Nadia Z HaqueUNKNOWN Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators
Aug 12, 2010·JAMA : the Journal of the American Medical Association·Alexander J KallenUNKNOWN Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program
Dec 7, 2010·International Journal of Antimicrobial Agents·Annie Wong-BeringerPaul Beringer
Dec 25, 2010·The American Journal of Medicine·Lindsey PritchardK Bruce Bayley
Apr 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nimish PatelThomas P Lodise
Apr 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ravina KullarMichael J Rybak

❮ Previous
Next ❯

Citations

Mar 14, 2012·European Journal of Clinical Pharmacology·Sepideh ElyasiAmirhooshang Mohammadpour
Aug 27, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Kenneth V I RolstonPamela White
Feb 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stan Deresinski
May 15, 2012·Antimicrobial Agents and Chemotherapy·Christine B TengDavid N Schwartz
Oct 8, 2013·Critical Care : the Official Journal of the Critical Care Forum·Matthieu LegrandJean-Luc Mainardi
Jan 5, 2014·Clinical Drug Investigation·Diane CappellettyRose Jung
Aug 30, 2014·European Journal of Clinical Pharmacology·Erik M van MaarseveenArthur R H van Zanten
Aug 20, 2014·Infectious Diseases and Therapy·Joseph J CarrenoSusan L Davis
Jun 21, 2015·Expert Review of Anti-infective Therapy·Young R LeeRonald G Hall
Jun 10, 2014·Advanced Drug Delivery Reviews·Manjunath P PaiThomas P Lodise
Apr 26, 2014·The American Journal of the Medical Sciences·Carlos A AlvarezRonald G Hall
Dec 2, 2014·The American Journal of the Medical Sciences·Sireesha KoppulaHarold M Szerlip
Feb 3, 2016·Clinical Therapeutics·Kristen E FoderoKari A Mergenhagen
Jun 5, 2013·The Journal of Surgical Research·Eric J LeyAli Salim
Oct 21, 2015·Surgical Infections·Stephen W DaviesRobert G Sawyer
Jan 15, 2013·International Journal of Antimicrobial Agents·Sheryl ZelenitskyUNKNOWN Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group
Aug 8, 2012·Burns : Journal of the International Society for Burn Injuries·David S GomezSilvia R C J Santos
Jan 31, 2012·Clinical Therapeutics·Ennie L CanoUNKNOWN Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group
Nov 18, 2014·Critical Care Medicine·Verônica T Costa e SilvaEmmanuel A Burdmann
Apr 23, 2013·Pharmacotherapy·Julie M CollinsJason C Gallagher
Oct 16, 2012·Pharmacotherapy·Michael A RuggeroJeffrey E Topal
Sep 26, 2015·JAAPA : Official Journal of the American Academy of Physician Assistants·Lawrence Carey
Nov 20, 2015·Journal of the Pediatric Infectious Diseases Society·Jennifer LeJohn Bradley
Sep 16, 2014·Pharmacotherapy·Joseph J CarrenoBen Lomaestro
Jul 15, 2015·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Mo-Han DongAi-Dong Wen
Dec 31, 2014·Expert Opinion on Pharmacotherapy·Sepideh ElyasiHamid Emadi-Koochak
Feb 12, 2013·International Journal of Antimicrobial Agents·Shruta RegeKimberly C Lindfield
Dec 6, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yosuke SuzukiJun-ichi Kadota
May 19, 2016·The Journal of Trauma and Acute Care Surgery·Ara KoEric J Ley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
T P LodiseG L Drusano
Clinical Therapeutics
Ennie L CanoImproving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group
International Journal of Antimicrobial Agents
Annie Wong-BeringerPaul Beringer
© 2021 Meta ULC. All rights reserved